2.50
Hdl Handle:
http://hdl.handle.net/10541/78000
Title:
Resistance to anti-VEGF agents.
Authors:
Ton, Nhuan C; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
The number of anti-angiogenic agents developed for clinical use has risen greatly over the past decade. Currently, more than 80 are in trials ranging from phase I through to phase III studies and many more are in preclinical evaluation. Much hope was envisaged for these new agents to become the panacea of anti-tumoural treatment. Unfortunately the single agent activity to date has proven to be disappointing although one trial has recently reported a survival advantage when chemotherapy was administered with anti-VEGF antibodies in the setting of advanced colorectal cancer. To an extent, this may be due to great expectations of cytostatic compounds, but recently many factors have been examined to explain the differences between clinical and experimental findings. In this review, some of the factors responsible for the discrepancy are examined, with a specific focus on inhibitors of VEGF. The key factors responsible for the lack of activity are tumour heterogeneity and redundancy in the VEGF signalling system. An increased understanding of these factors is critical to the development of effective anti-angiogenic agents and need to be taken into account as new generations of drugs emerge.
Affiliation:
Department of Medical Oncology, Cancer Research UK, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. Nton@picr.man.ac.uk
Citation:
Resistance to anti-VEGF agents. 2004, 10 (1):51-64 Curr. Pharm. Des.
Journal:
Current Pharmaceutical Design
Issue Date:
2004
URI:
http://hdl.handle.net/10541/78000
PubMed ID:
14754405
Type:
Article
Language:
en
ISSN:
1381-6128
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorTon, Nhuan C-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-08-20T11:25:43Z-
dc.date.available2009-08-20T11:25:43Z-
dc.date.issued2004-
dc.identifier.citationResistance to anti-VEGF agents. 2004, 10 (1):51-64 Curr. Pharm. Des.en
dc.identifier.issn1381-6128-
dc.identifier.pmid14754405-
dc.identifier.urihttp://hdl.handle.net/10541/78000-
dc.description.abstractThe number of anti-angiogenic agents developed for clinical use has risen greatly over the past decade. Currently, more than 80 are in trials ranging from phase I through to phase III studies and many more are in preclinical evaluation. Much hope was envisaged for these new agents to become the panacea of anti-tumoural treatment. Unfortunately the single agent activity to date has proven to be disappointing although one trial has recently reported a survival advantage when chemotherapy was administered with anti-VEGF antibodies in the setting of advanced colorectal cancer. To an extent, this may be due to great expectations of cytostatic compounds, but recently many factors have been examined to explain the differences between clinical and experimental findings. In this review, some of the factors responsible for the discrepancy are examined, with a specific focus on inhibitors of VEGF. The key factors responsible for the lack of activity are tumour heterogeneity and redundancy in the VEGF signalling system. An increased understanding of these factors is critical to the development of effective anti-angiogenic agents and need to be taken into account as new generations of drugs emerge.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAnimals-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshDrug Resistance, Neoplasm-
dc.subject.meshHumans-
dc.subject.meshNeoplasms-
dc.subject.meshNeovascularization, Pathologic-
dc.subject.meshPregnancy Proteins-
dc.subject.meshReceptors, Vascular Endothelial Growth Factor-
dc.subject.meshVascular Endothelial Growth Factors-
dc.titleResistance to anti-VEGF agents.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Cancer Research UK, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. Nton@picr.man.ac.uken
dc.identifier.journalCurrent Pharmaceutical Designen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.